Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Astrocyte elevated gene-1 induces breast cancer proliferation and invasion through upregulating HER2/neu expression.

Chinese medical journal·2012
Same author

Manipulating neural-stem-cell mobilization and migration in vitro.

Acta biomaterialia·2012
Same author

Inhibition of proliferation, viability, migration and invasion of gastric cancer cells by Aurora-A deletion.

Asian Pacific journal of cancer prevention : APJCP·2012
Same author

Repression of PDGF-R-α after cellular injury involves TNF-α, formation of a c-Fos-YY1 complex, and negative regulation by HDAC.

American journal of physiology. Cell physiology·2012
Same author

Single-stage posterior debridement and single-level instrumented fusion for spontaneous infectious spondylodiscitis of the lumbar spine.

Acta orthopaedica Belgica·2012
Same author

Cancer prevention health services research: an emerging field.

Journal of cancer education : the official journal of the American Association for Cancer Education·2012

Related Experiment Video

Updated: Jun 8, 2026

Complete Thymectomy in Adult Rats with Non-invasive Endotracheal Intubation
08:35

Complete Thymectomy in Adult Rats with Non-invasive Endotracheal Intubation

Published on: December 29, 2014

Myasthenia gravis appearing after thymectomy.

Xin-Gang Sun1, Yan-Li Wang, Yun-Hai Liu

  • 1Department of Neurology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha 410008, Hunan, China.

Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
|October 5, 2010
PubMed
Summary

Postoperative myasthenia gravis (MG) can develop after thymectomy, even without prior symptoms. Elevated anti-acetylcholine-receptor binding antibody (ARAb) titers post-surgery may indicate increased risk.

Related Experiment Videos

Last Updated: Jun 8, 2026

Complete Thymectomy in Adult Rats with Non-invasive Endotracheal Intubation
08:35

Complete Thymectomy in Adult Rats with Non-invasive Endotracheal Intubation

Published on: December 29, 2014

Area of Science:

  • Neurology
  • Immunology
  • Oncology

Background:

  • Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
  • Thymoma is a common cause of MG, often treated with thymectomy.
  • The risk of developing MG after thymectomy in patients without preoperative MG is not well understood.

Purpose of the Study:

  • To evaluate the clinical characteristics of patients who develop myasthenia gravis (MG) after thymectomy.
  • To identify potential risk factors for postoperative MG in thymoma patients.

Main Methods:

  • Retrospective study of 174 thymoma patients treated between 1990 and 2008.
  • Analysis of preoperative and postoperative myasthenia gravis (MG) status.
  • Measurement of anti-acetylcholine-receptor binding antibody (ARAb) titers.

Main Results:

  • 4.8% of patients without preoperative MG developed postoperative MG.
  • Elevated preoperative anti-acetylcholine-receptor binding antibody (ARAb) titers were observed in 17.6% of patients without preoperative MG.
  • Serum ARAb titers exacerbated in all six patients who developed postoperative MG.
  • Postoperative MG responded to treatment with anti-cholinesterase compounds and/or steroids.

Conclusions:

  • Thymectomy does not prevent the development of postoperative myasthenia gravis (MG).
  • Exacerbated anti-acetylcholine-receptor binding antibody (ARAb) levels post-thymectomy suggest extrathymic production.
  • A rise in ARAb titer may serve as a risk indicator for post-thymectomy MG.